Apr. 16 at 10:47 AM
$MLEC
AIGC clearly sees a profitable path forward. And will fast track the process with their current operations.
AIGC converted about 9 million dollars of preference shares into ordinary equity, taking de facto control (65.1%) and effectively locking in a major backer with a long‑term ag‑tech and biological‑inputs focus. That kind of concentrated ownership usually wants to:
Ramp production to prove commercial traction.
Secure early offtake deals or strategic partnerships to monetize the 45% GLA platform and new pea‑based proteins.
3. New pea‑based myoglobin breakthrough supports scaling
In April 2026, Moolec announced stable expression of bovine myoglobin in pea seeds, across multiple generations, validating its platform beyond safflower. The company explicitly frames this as a step toward scalable protein production in a globally adopted crop with existing supply chains, which fits a fast‑track commercialization playbook rather than pure R&D.
